T2 BIOSYSTMS INC (NASDAQ: TTOO)

T2 BIOSYSTMS INC

NASDAQ: TTOO (T2 Biosystems, Inc.)

Kemas kini terakhir: 15 Nov, 2024, 2:57AM

0.520

-0.03 (-5.11%)

Tambah ke senarai pantauan

Penutupan Terdahulu	0.548
Buka	0.588
Jumlah Dagangan	982,263
Purata Dagangan (3B)	486,011
Modal Pasaran	9,089,600

Harga / Pendapatan (P/E TTM)	0.018
Harga / Jualan (P/S)	0.800

Julat 52 Minggu	0.508 (-2%) — 8.38 (1511%)
Tarikh Pendapatan	13 Feb 2025 - 17 Feb 2025

Arah Aliran Pasaran

		Jangka Pendek	Jangka Sederhana
Industri	Diagnostics & Research (US)	Bercampur	Bercampur
	Diagnostics & Research (Global)	Bercampur	Bercampur
Stok	T2 Biosystems, Inc.	Bercampur	Menurun

AISkor Stockmoo

0.3

Konsensus Penganalisis	NA
Aktiviti Orang Dalam	NA
Volatiliti Harga	0.5
Purata Bergerak Teknikal	2.5
Osilator Teknikal	-2.0
Purata	0.33

Saham Serupa

Stok	Modal Pasaran	DY	P/E (TTM)	P/B
TTOO	9 M	-	0.018	-
OPK	989 M	-	-	0.710
FLGT	565 M	-	-	0.500
PSNL	562 M	-	-	1.63
ATLN	226 M	-	-	14.86
BDSX	215 M	-	-	7.62

T2 Biosystems Inc is a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes. It is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. The company’s products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the proprietary T2 Magnetic Resonance technology.
Sektor	Healthcare
Industri	Diagnostics & Research
Gaya Pelaburan	Small Value
% Dimiliki oleh Orang Dalam	4.45%
% Dimiliki oleh Institusi	74.65%

Tiada data dalam julat masa ini.

Tarikh	Jenis	Butiran
18 Dec 2024	Pengumuman	T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European Distributor
17 Dec 2024	Pengumuman	T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally
16 Dec 2024	Pengumuman	T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.
09 Dec 2024	Pengumuman	T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens
14 Nov 2024	Pengumuman	T2 Biosystems Announces Third Quarter 2024 Financial Results
05 Nov 2024	Pengumuman	T2 Biosystems to Report Third Quarter 2024 Financial Results and Business Updates on November 14, 2024
08 Oct 2024	Pengumuman	T2 Biosystems, Inc. and Prxcision, Inc. Announce Co-Marketing Collaboration for Rapid Direct-From-Blood Diagnostics and AI-Powered Decision Support Platform
08 Oct 2024	Pengumuman	T2 Biosystems to Host Business Update Call on October 10, 2024
07 Oct 2024	Pengumuman	T2 Biosystems Announces Exclusive U.S. Agreement with Cardinal Health to Sell its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens
07 Oct 2024	Pengumuman	T2 Biosystems Announces Preliminary Third Quarter 2024 Financial Results

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

Log masuk untuk menambahkan ke senarai pantauan

AI Templat

Peringatan harga anda

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Log masuk untuk menambahkan ke senarai pantauan

Keuntungan Nyata	-
Keuntungan Tidak Nyata	-
Dividen Diterima 2025	-
Jumlah Untung	-
Pulangan Purata	-
Kuantiti (Beli)	-
Purata Harga (Beli)	-
Kuantiti (Jual)	-
Purata Harga (Jual)	-

Log masuk untuk menambahkan ke senarai pantauan

Tiada saham yang memenuhi kriteria anda

Margin Operasi (TTM)	-490.52%
EPS Cair (TTM)	29.70
Pertumbuhan Hasil Suku Tahunan (YOY)	-0.60%

Nisbah Semasa (MRQ)	0.600
Aliran Tunai Operasi (OCF TTM)	-43.73 M
Aliran Tunai Bebas Leveraj (LFCF TTM)	-31.85 M

Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)